AUS
NZ
UK
CA
USA
IND
Highlights
- Apogee Therapeutics operates within the biotechnology sector, focused on medical innovation.
- Market capitalization of $2.23 billion with notable fluctuations in its stock price over the past year.
- Beta coefficient of 2.26 reflects higher stock price volatility compared to the broader market.
Apogee Therapeutics (NASDAQ:APGE) is part of the biotechnology sector, an industry driven by research and the development of new treatments based on biological processes. This sector encompasses firms that work to address unmet medical needs, often through innovations that can lead to new therapeutic approaches. Biotechnology companies are integral to advancing medicine through discoveries and therapies that can impact various diseases.
Stock Performance and Market Position
Shares of Apogee Therapeutics opened at $49.57, placing the stock within a specific range in terms of market valuation. The company holds a market capitalization of $2.23 billion, a common metric used to gauge the size of a firm. Apogee's price-to-earnings ratio of -20.48 indicates the firm is operating at a loss relative to its stock price. Additionally, the beta value of 2.26 suggests the stock is more volatile than the broader market, with its price subject to larger fluctuations based on overall market conditions.
Stock Price Movement
The stock of Apogee Therapeutics has experienced significant price movement over the past year, ranging from a low of $27.05 to a high of $72.29. This range reflects considerable variability in its price. The stock has shown a 50-day simple moving average of $48.87 and a 200-day simple moving average of $48.90. These averages are used to analyze short-term and long-term price trends and can indicate the general direction in which the stock has been moving over time.
Volatility and Risk Factors
With a beta value of 2.26, Apogee's stock is categorized as having higher volatility. A beta greater than one signifies that the stock tends to experience more pronounced price movements compared to the overall market. This heightened volatility is common in the biotechnology sector, where stock prices can be influenced by clinical trial results, regulatory decisions, and market sentiment surrounding the potential success of new therapies or products.
Key Financial Metrics
The market capitalization of Apogee, alongside its negative price-to-earnings ratio, suggests the company is in an early or development phase typical within the biotechnology field. Firms in this industry often experience financial losses during periods of intense research and development. These financial metrics provide an understanding of how the company is valued in the marketplace and offer insight into the challenges biotechnology companies face as they work toward commercialization of their innovations.
